961 related articles for article (PubMed ID: 35680848)
1. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).
He M; Cao C; Ni Z; Liu Y; Song P; Hao S; He Y; Sun X; Rao Y
Signal Transduct Target Ther; 2022 Jun; 7(1):181. PubMed ID: 35680848
[TBL] [Abstract][Full Text] [Related]
2. Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy.
Bhole RP; Kute PR; Chikhale RV; Bonde CG; Pant A; Gurav SS
Bioorg Chem; 2023 Oct; 139():106720. PubMed ID: 37480814
[TBL] [Abstract][Full Text] [Related]
3. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
4. PROTAC-DB 2.0: an updated database of PROTACs.
Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
[TBL] [Abstract][Full Text] [Related]
5. Chemistries of bifunctional PROTAC degraders.
Cao C; He M; Wang L; He Y; Rao Y
Chem Soc Rev; 2022 Aug; 51(16):7066-7114. PubMed ID: 35916511
[TBL] [Abstract][Full Text] [Related]
6. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
[TBL] [Abstract][Full Text] [Related]
7. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
8. In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs).
Tomoshige S; Ishikawa M
Bioorg Med Chem; 2021 Jul; 41():116221. PubMed ID: 34034148
[TBL] [Abstract][Full Text] [Related]
9. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
[TBL] [Abstract][Full Text] [Related]
10. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
[TBL] [Abstract][Full Text] [Related]
11. PROTACs: Novel approach for cancer breakdown by breaking proteins.
Memon H; Patel BM
Life Sci; 2022 Jul; 300():120577. PubMed ID: 35487303
[TBL] [Abstract][Full Text] [Related]
12. Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies.
Wu Y; Zhang J; Zhu X; Zhang Y
Cancer Lett; 2022 Sep; 544():215808. PubMed ID: 35764266
[TBL] [Abstract][Full Text] [Related]
13. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
[TBL] [Abstract][Full Text] [Related]
14. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
Yao R; Luo T; Wang M
Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
[TBL] [Abstract][Full Text] [Related]
15. Developments of PROTACs technology in immune-related diseases.
Wang C; Zhang Y; Deng J; Liang B; Xing D
Eur J Med Chem; 2023 Mar; 249():115127. PubMed ID: 36724631
[TBL] [Abstract][Full Text] [Related]
16. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
17. PROTAC degraders as chemical probes for studying target biology and target validation.
Němec V; Schwalm MP; Müller S; Knapp S
Chem Soc Rev; 2022 Sep; 51(18):7971-7993. PubMed ID: 36004812
[TBL] [Abstract][Full Text] [Related]
18. PROTAC-DB: an online database of PROTACs.
Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
[TBL] [Abstract][Full Text] [Related]
19. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
20. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
Kastl JM; Davies G; Godsman E; Holdgate GA
SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
